May 19, 2021 A new bioresorbable scaffold (Firesorb, MicroPort Medical), one with much thinner struts compared with first-generation “dissolving” devices, has shown some early promise in a study of patients with relatively simple coronary artery lesions. Presenting the results of FUTURE II as a late-breaking clinical trial at EuroPCR, Bo Xu, MBBS (National Clinical Research Center for Cardiovascular Disease/Peking Union Medical College, Beijing, China), reported that in this trial, which included operators adhering to a dedicated implantation technique, the bioresorbable scaffold was noninferior to a cobalt-chromium everolimus-eluting stent (Xience; Abbott Vascular) for the primary endpoint of in-segment late lumen loss. While FUTURE II is a small study looking solely at angiographic outcomes, Xu said he remains optimistic about the technology. “I think, although this is a very small sized study with angiographic outcomes is comparing a new device with a drug-eluting stent, this is always the first step,” he commented. “After the first-in-man randomized study, now we expanded the indication to test this new device in larger studies. However, we believe it [represents] an opportunity.”